Welcure Drugs & Pharmaceuticals Ltd

Welcure Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Welcure Drugs & Pharmaceuticals Ltd

₹ 4.87 0.00%
26 Apr - close price
Company website BSE: 524661
About

Incorporated in 1992, Welcure Drugs And Pharmaceuticals Ltd used to manufacture pharmaceuticals products[1]

Key Points

Business Overview:[1]
Company manufactures and markets pharmaceuticals formulations in the form of tablets, capsules, dry syrups, antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarial, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilizers, sedatives and gastrointestinal.

Website BSE
  • Market Cap ₹ 6.58 Cr.
  • Current Price ₹ 4.87
  • High / Low ₹ 5.48 / 3.20
  • Stock P/E
  • Book Value ₹ 5.05
  • Dividend Yield 0.00 %
  • ROCE -12.3 %
  • ROE -24.8 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Stock is trading at 0.96 times its book value
  • Company's working capital requirements have reduced from 74.6 days to 45.4 days

Cons

  • Company has low interest coverage ratio.
  • Company's cost of borrowing seems high

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008
16.36 24.67 25.67
17.92 25.91 27.68
Operating Profit -1.56 -1.24 -2.01
OPM % -9.54% -5.03% -7.83%
0.59 1.14 1.08
Interest 0.36 0.24 0.53
Depreciation 0.48 0.43 0.43
Profit before tax -1.81 -0.77 -1.89
Tax % -4.42% -11.69% -2.12%
-1.89 -0.86 -1.93
EPS in Rs -1.40 -0.64 -1.43
Dividend Payout % -0.00% -0.00% -0.00%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 4%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -124%
Stock Price CAGR
10 Years: 17%
5 Years: 60%
3 Years: 33%
1 Year: 19%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: -25%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008
Equity Capital 12.11 12.11 12.12
Reserves -2.49 -3.36 -5.29
3.79 3.73 2.76
4.74 7.01 7.76
Total Liabilities 18.15 19.49 17.35
6.70 6.41 6.02
CWIP -0.00 -0.00 -0.00
Investments 0.38 0.38 0.28
11.07 12.70 11.05
Total Assets 18.15 19.49 17.35

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008
-1.66 0.39 1.29
-1.22 -0.14 0.08
2.97 -0.28 -1.43
Net Cash Flow 0.09 -0.03 -0.06

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2006 Mar 2007 Mar 2008
Debtor Days 112.67 119.40 123.56
Inventory Days 75.70 28.81 12.58
Days Payable -0.00 -0.00 -0.00
Cash Conversion Cycle 188.37 148.20 136.14
Working Capital Days 110.21 68.35 45.36
ROCE % -4.09% -12.32%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
14.12% 14.12% 14.12% 14.12% 14.12% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00%
85.86% 85.86% 85.86% 85.86% 85.86% 99.98% 99.99% 99.99% 100.00% 100.00% 99.99% 100.00%
No. of Shareholders 16,52417,38018,90918,95120,46324,69929,07529,01329,25129,59329,95731,530

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports